Merck & Co., Inc. (MRK)

NYSE: MRK · IEX Real-Time Price · USD
129.48
+0.11 (0.09%)
At close: Jun 14, 2024, 4:00 PM
129.45
-0.03 (-0.02%)
After-hours: Jun 14, 2024, 7:50 PM EDT
0.09%
Market Cap 327.95B
Revenue (ttm) 61.40B
Net Income (ttm) 2.31B
Shares Out 2.53B
EPS (ttm) 0.90
PE Ratio 143.87
Forward PE 14.29
Dividend $3.08 (2.38%)
Ex-Dividend Date Jun 17, 2024
Volume 5,745,197
Open 129.16
Previous Close 129.37
Day's Range 128.64 - 129.90
52-Week Range 99.14 - 133.10
Beta 0.40
Analysts Buy
Price Target 133.00 (+2.72%)
Earnings Date Jul 30, 2024

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Variv... [Read more]

Sector Healthcare
Founded 2000
Employees 72,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $133.0, which is an increase of 2.72% from the latest price.

Price Target
$133.0
(2.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merck looks for next-generation opportunities in obesity

Merck is focused on second and third-generation opportunities in the cardiometabolic drugs market, which includes treatments for obesity, the drugmaker said at a healthcare conference on Tuesday.

3 days ago - Reuters

Final Trades: Nike, Merck, General Motors and the XLE

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: GMNKEXLE
7 days ago - CNBC Television

Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center

DARMSTADT, Germany--(BUSINESS WIRE)--Merck opened its expanded Life Science distribution center in Schnelldorf, Germany. The € 180 investment added 25,000 square meters to the site.

8 days ago - Business Wire

Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

9 days ago - Business Wire

What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck

Cancer vaccines are finally showing promise as Moderna and Merck touted promising data on an experimental skin cancer vaccine and the U.K. announced plans for a “landmark” scheme to test the technolog...

Other symbols: MRNA
10 days ago - Forbes

Moderna, Merck say vaccine improved survival in patients with deadly skin cancer

Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin canc...

Other symbols: MRNA
11 days ago - CNBC

Merck's Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company's oncology pipeline and focused approach to the research and development of po...

11 days ago - Business Wire

Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up

Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patient...

Other symbols: MRNA
11 days ago - Reuters

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or d...

Other symbols: MRNA
11 days ago - Accesswire

Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster

Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stag...

Other symbols: SMMT
15 days ago - Market Watch

Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference

CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.

Other symbols: JNJPFE
15 days ago - CNBC

Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...

15 days ago - Business Wire

Merck Signs MoU with KAIST to Advance Scientific Collaboration

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Techno...

16 days ago - Business Wire

Merck to Buy Eye Drug Startup For Up to $3 Billion. It's Doubling Down on Deals.

The pharmaceutical company agreed to buy eye drug company Eyebiotech for up to $3 billion as it moves to diversify its pipeline and intensifies its acquisition efforts.

16 days ago - Barrons

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for prior...

16 days ago - Business Wire

Merck to acquire eye drug company EyeBio for up to $3 bln

Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, in the latest acquisition by the U.S. drugmaker as it looks to boost growth.

16 days ago - Reuters

Merck to buy EyeBio in a deal that could valued at up to $3 billion

Merck & Co. Inc. MRK, -2.63% announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.

16 days ago - Market Watch

Merck to Acquire EyeBio

RAHWAY, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology...

16 days ago - Business Wire

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports

Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street Jo...

17 days ago - Reuters

Merck Announces Third-Quarter 2024 Dividend

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2024 Dividend.

17 days ago - Business Wire

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer.

17 days ago - Business Wire

HPV vaccine provides real benefits for men, analysis shows

Vaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and neck cancers and other malignancies, a new analysis shows, adding to the vaccine's proven benefit in p...

22 days ago - Reuters

HPV vaccine can have big benefits for men, research shows

A vaccine that's widely known to help protect women from cervical cancer can also offer big health benefits for men, new research shows.

22 days ago - Market Watch

Cramer says these 10 stocks helped the Dow briefly crack 40,000

CNBC's Jim Cramer listed ten stocks that helped the Dow Jones Industrial Average briefly top 40,000 on Thursday, a new high for the index.

Other symbols: AAPLAXPCATCVXGSJPMMSFT
4 weeks ago - CNBC

Trade Tracker: Joe Terranova buys Amgen and Merck

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys

Other symbols: AMGN
4 weeks ago - CNBC Television